Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
About the study
ECMO has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. However bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. The aim is to investigate the occurence of bleeding and its frequency according to the type of ECMO either veno-arterial or veno-venous. The investigators also want to assess the relation of bleeding with von Willebrand Factor defects.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- informed consent of patient or person in charge
- patient supplied by an ECMO for cardiac or respiratory failure and referred to Lille University Hospital
- patient affiliated to "french social security"
EXCLUSION CRITERIA
Exclusion Criteria:
- pregnant woman
- no consent
- no affiliation to
- patient affiliated to '
- preexisting bleeding disorders
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Von Willebrand Diseases
Age (in years)
18+
Participants needed
418
Est. Completion Date
May 31, 2026
Treatment type
Observational
Sponsor
University Hospital, Lille
ClinicalTrials.gov identifier
NCT03070912
Study number
201583
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?